Intellectual Property Law and Microbiology: Patenting Microorganisms and Genetic Material

Abstract

The intersection of intellectual property (IP) law and microbiology represents a critical frontier in biotechnology, driving innovation while posing profound ethical, legal, and practical challenges. This comprehensive review examines the evolution and current landscape of patenting microorganisms and genetic material. It begins by tracing the historical jurisprudential shift, notably the landmark U.S. Supreme Court case Diamond v. Chakrabarty (1980), which established that live, human-made microorganisms are patentable subject matter. The paper delves into the core patentability requirements—novelty, inventive step (non-obviousness), and industrial application (utility)—as they apply to biological entities, which often exist in nature but are modified by human intervention. Further, the review explores the unique logistical mechanisms for patenting microbiological inventions, specifically the international deposit system governed by the Budapest Treaty. A significant portion is dedicated to the contentious issue of gene patents, analyzing the legal arguments for and against the patenting of isolated DNA sequences and the impact of pivotal cases like Association for Molecular Pathology v. Myriad Genetics, Inc (2013), which drew a critical distinction between naturally occurring genes and synthetic cDNA. The analysis also addresses emerging issues, including patenting CRISPR-Cas9 gene-editing technologies, synthetic biology, and microbiomes. Finally, the paper confronts the ethical objections and policy concerns surrounding the privatization of the fundamental building blocks of life, including implications for research freedom, healthcare access, and global equity. The conclusion argues that while patent protection is an indispensable incentive for biotechnological advancement, a carefully calibrated legal framework is essential to balance private innovation with public good.